Andrew Shaoyu Chen is the managing partner of the Shanghai office of Arnold & Porter LLP, which is a large international law firm headquartered in Washington DC, with over 1,000 attorneys providing full legal services from 13 offices located in the US, Europe, and Asia.

Mr. Chen has over 20 years of experience in food and drug law, including serving in the US Food and Drug Administration (2000-2004) in Rockville, Maryland as Assistant Chief Counsel, and Amgen (2006-2010) in Thousand Oaks, CA as Senior Counsel. Mr. Chen was born and grew up in China, graduated from Peking University, and currently admitted to practice in Washington DC.

Leveraging this very unique experience, Mr. Chen has been effectively assisting life sciences companies doing business in China and the US to resolve the most challenging legal and regulatory issues, set out critical strategies and implementation plans, respond to ever-increasing government oversight, mitigate enforcement risks, and successfully conduct product licensing and collaboration, clinical trial, product registration, manufacturing, sales and marketing, pharmacovigilance, and pricing and reimbursement.

Mr. Chen has also been actively assisting, on a pro bono basis, the China National Medical Products Administration (NMPA, formerly known as CFDA and SFDA) and various academic organizations to better understand the US FDA framework, and help the NMPA to further reform and align with the leading international regulatory systems.


  • Identify the most efficient regulatory pathways and implementation strategies for the China market.
  • Counsel on the pros and cons of importation versus local manufacturing, focusing on technology transfer, licensing, and co-development issues.
  • Advise on product development in China, including regulatory submissions and oversight ethics committee review, clinical trial agreements, investigator meetings, informed consent, and subject injury compensation.
  • Assist in obtaining product registration and manufacturing authorizations, including seeking expedited review and facilitating regulatory negotiations.
  • Advise on data protection and marketing exclusivities in China, particularly those related to China's new drug monitoring period, to prevent imported drugs from being excluded from the Chinese market.
  • Assist on product launch and commercialization efforts, including advertising and promotion, wholesale and retail distribution, and pricing and reimbursement.
  • Assist on internal audits and responding to regulatory agency inspections on GLP, GCP, GMP, and GSP compliance, including pharmacovigilance and product recall.
  • Advise on anti-unfair competition issues.


Chambers Greater China Region
Life Sciences: International Firms (China) (2022–2023)
The Legal 500 Asia-Pacific
“Leading Lawyers”—Life Sciences and Healthcare: Foreign Firms (China) (2021–2023)
Chambers Asia-Pacific
Healthcare and Life Sciences: Foreign Firms (China) (2012-2021)


  • JD, University of Nebraska College of Law, 2000, Executive Editor, Nebraska Law Review
  • LLB, Peking University, 1985
  • District of Columbia
  • Chinese (Mandarin)

Email Disclaimer